Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects.

Combined Etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, ip. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice.
Raleukin (AMG-719) enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Combined Etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, ip. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice.
Raleukin (AMG-719) enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4.  [Content Brief]

  . McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9.  [Content Brief]

  . Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65.  [Content Brief]